Author(s): Spindler KL, Nielsen JN, Lindebjerg J, Brandslund I, Jakobsen A
Abstract Share this page
Abstract PURPOSE: Epidermal growth factor receptor (EGFR) has been associated with radioresistance in solid tumors. Recently a polymorphism in the Sp1 recognition site of the EGFR promoter region was identified. The present study investigated the predictive value of this polymorphism for the outcome of chemoradiation in locally advanced rectal cancer. METHODS AND MATERIALS: The study included 77 patients with locally advanced T3 rectal tumors. Treatment consisted of preoperative radiation therapy at a total tumor dose of 65 Gy and concomitant chemotherapy with Uftoral. Blood samples from 63 patients were evaluated for Sp1 -216 G/T polymorphism by polymerase chain reaction analysis. Forty-eight primary tumor biopsies were available for EGFR immunostaining. Patients underwent surgery 8 weeks after treatment. Pathologic response evaluation was performed according to the tumor regression grade (TRG) system. RESULTS: Forty-nine percent had major response (TRG1-2) and 51\% moderate response (TRG 3-4) to chemoradiation. The rates of major response were 34\% (10/29) in GG homozygote patients compared with 65\% (22/34) in patients with T containing variants (p=0.023). Fifty-eight percent of biopsies were positive for EGFR expression (28/48). The major response rates with regard to EGFR immunostaining were not significantly different. EGFR-positive tumors were found in 83\% of the GG homozygote patients compared with 38\% of patients with TT or GT variants (p=0.008). CONCLUSIONS: There was a significant correlation between EGFR Sp1 -216 G/T polymorphism and treatment response to chemoradiation in locally advanced rectal cancer. Further investigations of a second set of patient and other treatment schedules are warranted.
This article was published in Int J Radiat Oncol Biol Phys
and referenced in Atherosclerosis: Open Access